Invasive pneumococcal disease: From a tertiary care hospital in the post-vaccine era


BASARANOGLU S. T. , ONCEL E. K. , Aykac K. , ÖZSÜREKCİ Y. , CENGİZ A. B. , KARA A. , ...Daha Fazla

HUMAN VACCINES & IMMUNOTHERAPEUTICS, cilt.13, ss.962-964, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 13 Konu: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/21645515.2016.1256519
  • Dergi Adı: HUMAN VACCINES & IMMUNOTHERAPEUTICS
  • Sayfa Sayıları: ss.962-964

Özet

A breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received 1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among 6 patients with invasive pneumococcal infection, 2 patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in 2 strains.